JonesResearch analyst Justin Walsh initiated coverage of RenovoRx (RNXT) with a Buy rating and $8 price target RenovoRx is a commercial stage medical technology company with an FDA-cleared dual-balloon catheter, RenovoCath, designed to improve delivery of anti-cancer drugs to tumors with poor blood supply, the analyst tells investors in a research note. The firm sees the device being “particularly useful” for treating pancreatic cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT: